What it's for (Indications)
- Docetaxel is indicated for the treatment of locally advanced or metastatic breast cancer, adjuvant treatment of breast cancer, non-small cell lung cancer (after platinum therapy failure or in chemotherapy-naive patients), castration-resistant prostate cancer, gastric carcinoma, and squamous cell carcinoma of the head and neck.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Administer docetaxel intravenously over 1 hour every 3 weeks in a facility equipped to manage possible complications (e.g., anaphylaxis). Do not substitute BEIZRAY for other docetaxel products. * **Locally Advanced or Metastatic Breast Cancer**: 60 mg/m² to 100 mg/m² as a single agent. * **Adjuvant Breast Cancer**: 75 mg/m² administered 1 hour after doxorubicin 50 mg/m² and cyclophosphamide 500 mg/m² every 3 weeks for 6 cycles. * **Non-Small Cell Lung Cancer (NSCLC)**: After platinum therapy failure: 75 mg/m² as a single agent. Chemotherapy-naive: 75 mg/m² followed by cisplatin 75 mg/m². * **Castration-Resistant Prostate Cancer (CRPC)**: 75 mg/m² with 5 mg prednisone twice a day continuously. * **Gastric Carcinoma (GC)**: 75 mg/m² followed by cisplatin 75 mg/m² (both on day 1 only) followed by fluorouracil 750 mg/m² per day as a 24-hour IV (days 1-5), starting at the end of cisplatin infusion. * **Squamous Cell Carcinoma of the Head and Neck (SCCHN)**: 75 mg/m² followed by cisplatin 75 mg/m² IV (day 1), followed by fluorouracil 750 mg/m² per day as a 24-hour IV (days 1-5), starting at the end of cisplatin infusion. |
Safety & Warnings
Common Side Effects
- The most serious adverse reactions associated with docetaxel include toxic deaths, hepatic impairment, hematologic effects (such as neutropenia), enterocolitis and neutropenic colitis, severe hypersensitivity reactions (including anaphylaxis), fluid retention, second primary malignancies, cutaneous reactions, neurologic reactions, eye disorders, asthenia, and tumor lysis syndrome.
- Common adverse reactions across all indications include infection.
Serious Warnings
- Black Box Warning: WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, and FLUID RETENTION. Treatment-related mortality associated with docetaxel is increased in patients with abnormal liver function, in patients receiving higher doses, and in patients with non-small cell lung carcinoma and a history of prior treatment with platinum-based chemotherapy who receive docetaxel as a single agent at a dose of 100 mg/m². Avoid the use of docetaxel in patients with abnormal liver function.
- Docetaxel carries warnings regarding: increased treatment-related mortality (toxic deaths), particularly in patients with abnormal liver function, higher doses, or NSCLC patients with prior platinum-based chemotherapy at 100 mg/m²; significant hepatic impairment; severe hematologic effects, notably neutropenia (requiring baseline neutrophil counts); enterocolitis and neutropenic colitis; potentially life-threatening hypersensitivity reactions; severe fluid retention; the risk of second primary malignancies; various cutaneous reactions; neurologic toxicities; eye disorders; asthenia; and tumor lysis syndrome.
- The alcohol content in certain formulations may also be a consideration.
- Administration should occur in a facility prepared to manage acute complications.
How it Works (Mechanism of Action)
Docetaxel is a semisynthetic taxane antineoplastic agent that exerts its cytotoxic effects primarily through a distinct mechanism involving microtubules, which are essential components of the cellular cytoskeleton. This drug promotes the assembly of tubulin into stable microtubules and simultaneously inhibits their depolymerization. By stabilizing these microtubule structures, docetaxel disrupts the dynamic equilibrium of the cellular microtubule network, which is critical for various cellular processes, including cell division, intracellular transport, and cell motility. Specifically, this sustained stabilization prevents the formation of a functional mitotic spindle apparatus, arresting cancer cells in the G2/M phase of the cell cycle. This prolonged mitotic arrest ultimately triggers cascades leading to programmed cell death (apoptosis) in susceptible tumor cells, thereby inhibiting proliferation. Its binding site is primarily on the beta-tubulin subunit within assembled microtubules, influencing microtubule dynamics in a manner distinct from agents that inhibit assembly.